## Maurizio Gasparini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3049277/publications.pdf Version: 2024-02-01

		57681	34195
135	11,133	46	103
papers	citations	h-index	g-index
139	139	139	7209
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial. European Heart Journal, 2021, 42, 4731-4739.	1.0	111
2	Sex differences in implantable cardiac defibrillator therapy according to arrhythmia detection times. Heart, 2020, 106, 520-526.	1.2	4
3	Second European Society of Cardiology Cardiac Resynchronization Therapy Survey: the Italian cohort. Journal of Cardiovascular Medicine, 2020, 21, 634-640.	0.6	1
4	Adherence to ESC cardiac resynchronization therapy guidelines: findings from the ESC CRT Survey II. Europace, 2020, 22, 932-938.	0.7	8
5	Favorable Trend of Implantable Cardioverterâ€Defibrillator Service Life in a Large Singleâ€Nation Population: Insights From 10â€Year Analysis of the Italian Implantable Cardioverterâ€Defibrillator Registry. Journal of the American Heart Association, 2019, 8, e012759.	1.6	13
6	Sex-Related Procedural Aspects and Complications in CRT Survey II. JACC: Clinical Electrophysiology, 2019, 5, 1048-1058.	1.3	12
7	Adaptive Cardiac Resynchronization Therapy Reduces Atrial Fibrillation Incidence in Heart Failure Patients With Prolonged AV Conduction. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007260.	2.1	14
8	Sexâ€ <b>s</b> pecific Differences in Survival and Heart Failure HospitalizationÂAfter Cardiac Resynchronization Therapy With or Without Defibrillation. Journal of the American Heart Association, 2019, 8, e013485.	1.6	11
9	CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients—who is doing what to whom and how?. European Journal of Heart Failure, 2018, 20, 1039-1051.	2.9	107
10	Atrioventricular junction ablation in patients with atrial fibrillation treated with cardiac resynchronization therapy: positive impact on ventricular arrhythmias, implantable cardioverterâ€defibrillator therapies and hospitalizations. European Journal of Heart Failure, 2018, 20, 1472-1481.	2.9	39
11	Atrial fibrillation and cardiac resynchronization therapy. Current Opinion in Cardiology, 2018, 33, 1-6.	0.8	4
12	Left univentricular pacing for cardiac resynchronization therapy. Europace, 2017, 19, euw179.	0.7	13
13	Adaptive CRT in patients with normal AV conduction and left bundle branch block: Does QRS duration matter?. International Journal of Cardiology, 2017, 240, 297-301.	0.8	18
14	The economic impact of battery longevity in implantable cardioverter-defibrillators for cardiac resynchronization therapy: the hospital and healthcare system perspectives. Europace, 2017, 19, 1349-1356.	0.7	9
15	The increased risk of stroke/transient ischemic attack in women with a cardiac implantable electronic device is not associated with a higher atrial fibrillation burden. Europace, 2017, 19, 1767-1775.	0.7	5
16	Long-term requirement for pacemaker implantation after cardiac valve replacement surgery. Heart Rhythm, 2017, 14, 529-534.	0.3	48
17	Continuous optimization of cardiac resynchronization therapy reduces atrial fibrillation in heart failure patients: Results of the Adaptive Cardiac Resynchronization Therapy Trial. Heart Rhythm, 2017, 14, 1820-1825.	0.3	51
18	Atrioventricular Node Ablation. Heart Failure Clinics, 2017, 13, 193-198.	1.0	3

#	Article	IF	CITATIONS
19	Long Detection Programming in Single-Chamber Defibrillators Reduces Unnecessary Therapies and Mortality. JACC: Clinical Electrophysiology, 2017, 3, 1275-1282.	1.3	21

20 Multipoint Pacing versus conventional ICD in Patients with a Narrow QRS complex (MPP Narrow QRS) Tj ETQq0 0 0.78BT /Overlock 10 Tr

21	2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverterâ€defibrillator programming and testing. Journal of Arrhythmia, 2016, 32, 1-28.	0.5	34
22	Different impact of long-detection interval and anti-tachycardia pacing in reducing unnecessary shocks: data from the ADVANCE III trial. Europace, 2016, 18, 1719-1725.	0.7	29
23	Prognostic implications of mitral regurgitation in patients after cardiac resynchronization therapy. European Journal of Heart Failure, 2016, 18, 1060-1068.	2.9	30
24	2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Heart Rhythm, 2016, 13, e50-e86.	0.3	197
25	Reduction of inappropriate anti-tachycardia pacing therapies and shocks by a novel suite of detection algorithms in heart failure patients with cardiac resynchronization therapy defibrillators: a historical comparison of a prospective database. Europace, 2016, 18, 1391-1398.	0.7	4
26	2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Europace, 2016, 18, 159-183.	0.7	135
27	Ventricular antitachycardia pacing therapy in patients with heart failure implanted with a cardiac resynchronization therapy defibrillator device: Efficacy, safety, and impact on mortality. Heart Rhythm, 2016, 13, 472-480.	0.3	6
28	Validation of a simple risk stratification tool for patients implanted with Cardiac Resynchronization Therapy: the <scp>VALIDâ€CRT</scp> risk score. European Journal of Heart Failure, 2015, 17, 717-724.	2.9	41
29	Longevity of implantable cardioverter-defibrillators for cardiac resynchronization therapy in current clinical practice: an analysis according to influencing factors, device generation, and manufacturer. Europace, 2015, 17, 1251-1258.	0.7	37
30	European Cardiac Resynchronization Therapy Survey II: rationale and design. Europace, 2015, 17, 137-141.	0.7	22
31	Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction. European Journal of Heart Failure, 2015, 17, 135-143.	2.9	21
32	Atrioventricular Node Ablation. Cardiac Electrophysiology Clinics, 2015, 7, 749-754.	0.7	0
33	Device-detected atrial fibrillation and risk for stroke: an analysis of >10 000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted) Tj ETQq1 1 0.7	84 <b>3.</b> b4 rgE	BT /@ww.erlock
34	Association of Long vs Standard Detection Intervals for Implantable Cardioverter-Defibrillators With Hospitalizations and Costs. JAMA - Journal of the American Medical Association, 2014, 312, 555.	3.8	7
35	Decline of defibrillation testing in the clinical practice: an 8-year nation-wide assessment. Europace, 2014, 16, 1103-1104.	0.7	10
36	Complete atrioventricular block DOES reduce mortality in patients with atrial fibrillation treated with cardiac resynchronization therapy. European Journal of Heart Failure, 2014, 16, 114-114.	2.9	5

#	Article	IF	CITATIONS
37	Letter by Gasparini Regarding Article, "Syncope in High-Risk Cardiomyopathy Patients With Implantable Defibrillators: Frequency, Risk Factors, Mechanisms, and Association With Mortality: Results From the Multicenter Automatic Defibrillator Implantation Trial–Reduce Inappropriate Therapy (MADIT-RIT) Studyâ€: Circulation, 2014, 130, e132.	1.6	0
38	Ventricular rate monitoring as a tool to predict and prevent atrial fibrillation-related inappropriate shocks in heart failure patients treated with cardiac resynchronisation therapy defibrillators. Heart, 2014, 100, 848-854.	1.2	14
39	Identification of Genetic Markers for Treatment Success in Heart Failure Patients. Circulation: Cardiovascular Genetics, 2014, 7, 760-770.	5.1	32
40	Determinants of All-Cause Mortality in Different Age Groups in Patients With Severe Systolic Left Ventricular Dysfunction Receiving an Implantable Cardioverter Defibrillator (from the Italian) Tj ETQq0 0 0 rgBT 1691-1696	Overlock 0.7	10 Tf 50 622 <sup>-</sup>
41	Absolute survival after cardiac resynchronization therapy according to baseline QRS duration: A multinational 10-year experience. American Heart Journal, 2014, 167, 203-209.e1.	1.2	22
42	Efficacy of Long Detection Interval Implantable Cardioverter-Defibrillator Settings in Secondary Prevention Population. Circulation, 2014, 130, 308-314.	1.6	68
43	Avoiding Unnecessary Aggressive ICD Programming After MADIT-RIT and ADVANCE III Trials. Journal of the American College of Cardiology, 2014, 63, 189-190.	1.2	4
44	Reply to letter to the editor by Goel and Kapoor. American Heart Journal, 2014, 167, e17.	1.2	0
45	Effect of Long-Detection Interval vs Standard-Detection Interval for Implantable Cardioverter-Defibrillators on Antitachycardia Pacing and Shock Delivery. JAMA - Journal of the American Medical Association, 2013, 309, 1903.	3.8	359
46	Device Therapy in Heart Failure. Journal of the American College of Cardiology, 2013, 61, 945-947.	1.2	8
47	Cardiac resynchronization therapy-defibrillator improves long-term survival compared with cardiac resynchronization therapy-pacemaker in patients with a class IA indication for cardiac resynchronization therapy: data from the Contak Italian Registry. Europace, 2013, 15, 1273-1279.	0.7	45
48	Clinical outcomes with synchronized left ventricular pacing: Analysis of the adaptive CRT trial. Heart Rhythm, 2013, 10, 1368-1374.	0.3	139
49	Cardiac Resynchronization Therapy in Patients With Atrial Fibrillation. JACC: Heart Failure, 2013, 1, 500-507.	1.9	147
50	Letter by Gasparini and Boriani Regarding Article, "Cardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation: Results From the Resynchronization for Ambulatory Heart Failure Trial (RAFT)― Circulation: Heart Failure, 2013, 6, e22.	1.6	4
51	The importance of increased percentage of biventricular pacing to improve clinical outcomes in patients receiving cardiac resynchronization therapy. Current Opinion in Cardiology, 2013, 28, 50-54.	0.8	21
52	The values of defibrillation testing at implantable cardioverter defibrillator implantation. Current Opinion in Cardiology, 2012, 27, 8-12.	0.8	8
53	Improving Thromboprophylaxis Using Atrial Fibrillation Diagnostic Capabilities in Implantable Cardioverter-Defibrillators. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 182-188.	0.9	33
54	The European CRT Survey: 1 year (9–15 months) followâ€up results. European Journal of Heart Failure, 2012, 14, 61-73.	2.9	87

#	Article	IF	CITATIONS
55	Metaâ€analysis of randomized controlled trials evaluating left ventricular vs. biventricular pacing in heart failure: effect on allâ€cause mortality and hospitalizations. European Journal of Heart Failure, 2012, 14, 652-660.	2.9	45
56	Huge left atrial thrombus after left atrial appendage occlusion with a Watchman device. European Heart Journal, 2012, 33, 1998-1998.	1.0	13
57	Clinical Evaluation of Defibrillation Testing in an Unselected Population of 2,120 Consecutive Patients Undergoing First Implantable Cardioverter-Defibrillator Implant. Journal of the American College of Cardiology, 2012, 60, 981-987.	1.2	71
58	Investigation of a novel algorithm for synchronized left-ventricular pacing and ambulatory optimization of cardiac resynchronization therapy: Results of the adaptive CRT trial. Heart Rhythm, 2012, 9, 1807-1814.e1.	0.3	223
59	Low-dose dobutamine test associated with interventricular dyssynchrony: A useful tool to identify cardiac resynchronization therapy responders. American Heart Journal, 2012, 163, 422-429.	1.2	24
60	A novel algorithm for individualized cardiac resynchronization therapy: Rationale and design of the adaptive cardiac resynchronization therapy trial. American Heart Journal, 2012, 163, 747-752.e1.	1.2	54
61	Risk Stratification in Brugada Syndrome. Journal of the American College of Cardiology, 2012, 59, 37-45.	1.2	523
62	AV Junction Ablation in Heart Failure Patients With Atrial Fibrillation Treated With Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2012, 59, 727-729.	1.2	13
63	Genetic Variants of the Renin-Angiotensin-Aldosterone SystemÂand Reverse Remodeling After Cardiac Resynchronization Therapy. Journal of Cardiac Failure, 2012, 18, 762-768.	0.7	10
64	Implantable cardioverter defibrillator harm?. Europace, 2012, 14, 1087-1093.	0.7	10
65	Impact of Mitral Regurgitation on the Outcome of Patients Treated with CRTâ€D: Data from the InSync ICD Italian Registry. PACE - Pacing and Clinical Electrophysiology, 2012, 35, 146-154.	0.5	17
66	Device-Detected Atrial Tachyarrhythmias Predict Adverse Outcome in Real-World Patients With Implantable Biventricular Defibrillators. Journal of the American College of Cardiology, 2011, 57, 167-172.	1.2	116
67	Comparison of the Usefulness of Cardiac Resynchronization Therapy in Three Age-Groups (<65, 65-74) Tj ETQq1 1510-1516.	1 0.7843 0.7	14 rgBT /〇 30
68	Incidence and clinical relevance of uncontrolled ventricular rate during atrial fibrillation in heart failure patients treated with cardiac resynchronization therapy. European Journal of Heart Failure, 2011, 13, 868-876.	2.9	53
69	Long-Term Complications Related to Biventricular Defibrillator Implantation. Circulation, 2011, 123, 2526-2535.	1.6	80
70	Lowâ€Dose Dobutamine Stress Echocardiography to Assess Left Ventricular Contractile Reserve for Cardiac Resynchronization Therapy: Data From the Lowâ€Dose Dobutamine Stress Echocardiography to Predict Cardiac Resynchronization Therapy Response (LODO RT) Trial. Congestive Heart Failure, 2010, 16, 104-110	2.0	12
71	Atrial arrhythmias after cardiac resynchronization therapy: an inverse correlation with achieving 100% biventricular pacing and cardiac resynchronization therapy effectiveness. Europace, 2010, 12, 9-10.	0.7	9
72	Who Are the Long-QT Syndrome Patients Who Receive an Implantable Cardioverter-Defibrillator and What Happens to Them?. Circulation, 2010, 122, 1272-1282.	1.6	261

MAURIZIO GASPARINI

#	Article	IF	CITATIONS
73	2010 Focused Update of ESC Guidelines on device therapy in heart failure. European Journal of Heart Failure, 2010, 12, 1143-1153.	2.9	152
74	Resumption of sinus rhythm in patients with heart failure and permanent atrial fibrillation undergoing cardiac resynchronization therapy: a longitudinal observational study. European Heart Journal, 2010, 31, 976-983.	1.0	77
75	Presence of left ventricular contractile reserve predicts midterm response to cardiac resynchronization therapy—results from the LOw dose DObutamine Stress-Echo Test in Cardiac Resynchronization Therapy (LODO-CRT) Trial. Heart Rhythm, 2010, 7, 1600-1605.	0.3	27
76	BIVentricular versus right ventricular antitachycardia pacing to terminate ventricular tachyarrhythmias in patients receiving cardiac resynchronization therapy: The ADVANCE CRT-D Trial. American Heart Journal, 2010, 159, 1116-1123.e2.	1.2	51
77	2010 Focused Update of ESC Guidelines on device therapy in heart failure. Europace, 2010, 12, 1526-1536. A simplified biventricular defibrillator with fixed long detection intervals reduces implantable	0.7	297
78	cardioverter defibrillator (ICD) interventions and heart failure hospitalizations in patients with non-ischaemic cardiomyopathy implanted for primary prevention: the RELEVANT [Role of long dEtection window programming in patients with LEft VentriculAr dysfunction, Non-ischemic eTiology in primary prevention treated with a biventricular ICD] study. European Heart Journal, 2009, 30,	1.0	149
79	2758-2767. Cardiac resynchronization therapy in heart failure patients with atrial fibrillation. Europace, 2009, 11, v82-v86.	0.7	43
80	Effectiveness of cardiac resynchronization therapy in heart failure patients with valvular heart disease: comparison with patients affected by ischaemic heart disease or dilated cardiomyopathy. The InSync/InSync ICD Italian Registry. European Heart Journal, 2009, 30, 2275-2283.	1.0	21
81	Indications for the use of diagnostic implantable and external ECG loop recorders. Europace, 2009, 11, 671-687.	0.7	309
82	Use of Implantable Cardioverterâ€Defibrillator in Inherited Arrhythmogenic Diseases: Data from Italian ICD Registry for the Years 2001–6. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 434-445.	0.5	16
83	Avoid Delivering Therapies for Nonsustained Fast Ventricular Tachyarrhythmia in Patients with Implantable Cardioverter/Defibrillator: The ADVANCE III Trial. Journal of Cardiovascular Electrophysiology, 2009, 20, 663-666.	0.8	22
84	Followâ€Up of CRTâ€ICD: Implications for the Use of Remote Followâ€Up Systems. Data from the InSync ICD Italian Registry. PACE - Pacing and Clinical Electrophysiology, 2008, 31, 38-46.	0.5	32
85	Insulinâ€Treated Type 2 Diabetes Is Associated with a Decreased Survival in Heart Failure Patients after Cardiac Resynchronization Therapy. PACE - Pacing and Clinical Electrophysiology, 2008, 31, 1425-1432.	0.5	31
86	Persistent Atrial Fibrillation Worsens Heart Rate Variability, Activity and Heart Rate, as Shown by a Continuous Monitoring by Implantable Biventricular Pacemakers in Heart Failure Patients. Journal of Cardiovascular Electrophysiology, 2008, 19, 693-701.	0.8	27
87	Antiarrhythmic Effect of Reverse Ventricular Remodeling Induced by Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2008, 52, 1442-1449.	1.2	96
88	Remission of left ventricular systolic dysfunction and of heart failure symptoms after cardiac resynchronization therapy: Temporal pattern and clinical predictors. American Heart Journal, 2008, 155, 507-514.	1.2	60
89	Efficacy of LOw-dose DObutamine Stress-Echocardiography to predict Cardiac Resynchronization Therapy Response (LODO-CRT) multicenter prospective study—Design and rationale. American Heart Journal, 2008, 156, 656-661.	1.2	7
90	Electrical storm in patients with biventricular implantable cardioverter defibrillator: Incidence, predictors, and prognostic implications. American Heart Journal, 2008, 156, 847-854.	1.2	28

#	Article	IF	CITATIONS
91	Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. European Heart Journal, 2008, 29, 1644-1652.	1.0	248
92	Heart rate variability monitored by the implanted device predicts response to CRT and longâ€ŧerm clinical outcome in patients with advanced heart failure. European Journal of Heart Failure, 2008, 10, 1073-1079.	2.9	33
93	Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in Collaboration with the European Heart Rhythm Association. European Heart Journal, 2007, 28, 2256-2295.	1.0	677
94	Defibrillation testing at the time of implantation of cardioverter defibrillator in the clinical practice: a nation-wide survey. Europace, 2007, 9, 540-543.	0.7	48
95	Efficacy of cardiac resynchronization therapy in very old patients: the Insync/Insync ICD Italian Registry. Europace, 2007, 9, 732-738.	0.7	36
96	Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in Collaboration with the European Heart Rhythm Association. Europace, 2007, 9, 959-998.	0.7	278
97	Three Years of Cardiac Resynchronization Therapy: Could Superior Benefits be Obtained in Patients with Heart Failure and Narrow QRS?. PACE - Pacing and Clinical Electrophysiology, 2007, 30, S34-9.	0.5	13
98	Long-Term Survival of Patients With Heart Failure and Ventricular Conduction Delay Treated With Cardiac Resynchronization Therapy. American Journal of Cardiology, 2007, 99, 232-238.	0.7	87
99	Comparison of the Effects of Cardiac Resynchronization Therapy in Patients With Class II Versus Class III and IV Heart Failure (from the InSync/InSync ICD Italian Registry)â€â€Conflicts of interest: Sergio Valsecchi and Alessandra Denaro are employees of Medtronic Italia, Rome, Italy.,â€jâ€jA list of centers and investigators participating in the InSync/InSync ICD Italian Registry is provided in the Appendix	0.7	39
100	Current Practice in Italy of VF Testing at Implant: What Do We Know and Where Do We Go From Here?. , 2007, , 231-237.		0
101	Four-Year Efficacy of Cardiac Resynchronization Therapy on Exercise Tolerance and Disease Progression. Journal of the American College of Cardiology, 2006, 48, 734-743.	1.2	371
102	Clinical predictors of marked improvement in left ventricular performance after cardiac resynchronization therapy in patients with chronic heart failure. American Heart Journal, 2006, 151, 477.e1-477.e6.	1.2	42
103	Characteristics of ventricular tachyarrhythmias occurring in ischemic versus nonischemic patients implanted with a biventricular cardioverter-defibrillator for primary or secondary prevention of sudden death. American Heart Journal, 2006, 152, 527.e1-527.e11.	1.2	11
104	Comparison of 1-year effects of left ventricular and biventricular pacing in patients with heart failure who have ventricular arrhythmias and left bundle-branch block: The Bi vs Left Ventricular Pacing: An International Pilot Evaluation on Heart Failure Patients with Ventricular Arrhythmias (BELIEVE) multicenter prospective randomized pilot study. American Heart Journal, 2006, 152,	1.2	83
105	Right Ventricular versus Biventricular Antitachycardia Pacing in the Termination of Ventricular Tachyarrhythmia in Patients Receiving Cardiac Resynchronization Therapy: The ADVANCE CRT-D Trial. Journal of Cardiovascular Electrophysiology, 2006, 17, 504-507.	0.8	5
106	Atrial Fibrillation Burden During the Post-Implant Period After CRT Using Device-Based Diagnostics. Journal of Cardiovascular Electrophysiology, 2006, 17, 813-817.	0.8	48
107	Clustering of Ventricular Tachyarrhythmias in Heart Failure Patients Implanted with a Biventricular Cardioverter Defibrillator. Journal of Cardiovascular Electrophysiology, 2006, 17, 1299-1306.	0.8	18
108	To the Editor:. Journal of Cardiovascular Electrophysiology, 2006, 17, 457-457.	0.8	0

#	Article	IF	CITATIONS
109	Long-Term Survival in Patients Treated with Cardiac Resynchronization Therapy: A 3-Year Follow-Up Study from the InSync/InSync ICD Italian Registry. PACE - Pacing and Clinical Electrophysiology, 2006, 29, S2-S10.	0.5	34
110	Hiccups and Dysphonic Metallic Voice. Circulation, 2006, 114, e534-5.	1.6	17
111	Delayed Defibrillation Testing in Patients Implanted with Biventricular ICD (CRT-D): A Reliable and Safe Approach. Journal of Cardiovascular Electrophysiology, 2006, .	0.8	0
112	Endocardial Implantation of a Cardioverter Defibrillator in Early Childhood. Journal of Cardiovascular Electrophysiology, 2006, .	0.8	0
113	Endocardial Implantation of a Cardioverter Defibrillator in Early Childhood. Journal of Cardiovascular Electrophysiology, 2005, 16, 1381-1383.	0.8	5
114	Delayed Defibrillation Testing in Patients Implanted with Biventricular ICD (CRTâ€Đ): A Reliable and Safe Approach. Journal of Cardiovascular Electrophysiology, 2005, 16, 1279-1283.	0.8	19
115	Endocardial Implantation of a Cardioverter-Defibrillator in a 13-Month-Old Child Affected by Long-QT Syndrome and Syndactyly. Circulation, 2004, 110, e525-7.	1.6	6
116	Cardiac resynchronization therapy in patients with narrow QRS. Journal of the American College of Cardiology, 2004, 44, 2096.	1.2	2
117	Cardiac Resynchronization and Implantable Cardioverter Defibrillator Therapy: Preliminary Results from the InSync Implantable Cardioverter Defibrillator Italian Registry. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 148-151.	0.5	17
118	Is the Left Ventricular Lateral Wall the Best Lead Implantation Site for Cardiac Resynchronization Therapy?. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 162-168.	0.5	77
119	Beneficial Effects of Biventricular Pacing in Patients with a "Narrow" QRS. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 169-174.	0.5	60
120	Is the Outcome of Cardiac Resynchronization Therapy Related to the Underlying Etiology?. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 175-180.	0.5	101
121	Relief of Drug Refractory Angina by Biventricular Pacing in Heart Failure. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 181-184.	0.5	10
122	Biventricular Pacing via a Persistent Left Superior Vena Cava: Report of Four Cases. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 192-196.	0.5	27
123	Flecainide Test in Brugada Syndrome: A Reproducible but Risky Tool. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 338-341.	0.5	92
124	Clinical and Molecular Characterization of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation, 2002, 106, 69-74.	1.6	1,103
125	Natural History of Brugada Syndrome. Circulation, 2002, 105, 1342-1347.	1.6	984
126	Programmed Electrical Stimulation in Brugada Syndrome: How Reproducible Are the Results?. Journal of Cardiovascular Electrophysiology, 2002, 13, 880-887.	0.8	52

MAURIZIO GASPARINI

#	Article	IF	CITATIONS
127	Longâ€Term Followâ€Up After Atrioventricular Nodal Ablation and Pacing: Low Incidence of Sudden Cardiac Death. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 1925-1929.	0.5	20
128	Noncontact Systemâ€Guided Simplified Right Atrial Linear Lesions Using Radiofrequency Transcatheter Ablation for Treatment of Refractory Atrial Fibrillation. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 1843-1847.	0.5	9
129	Inferior Vena Cava Loop of the Implantable Cardioverter Defibrillator Endocardial Lead: A Possible Solution to the Growth Problem in Pediatric Implantation. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 2108-2112.	0.5	24
130	Clinical and Genetic Heterogeneity of Right Bundle Branch Block and ST-Segment Elevation Syndrome. Circulation, 2000, 102, 2509-2515.	1.6	490
131	Thromboembolism after atrioventricular node ablation and pacing: long term follow up. Heart, 1999, 82, 494-498.	1.2	13
132	Congestive Heart Failure Induced by Recipient Atrial Tachycardia Conducted to the Donor Atrium after Orthotopic Heart Transplantation Journal of Cardiovascular Electrophysiology, 1999, 10, 399-404.	0.8	21
133	Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion. Journal of the American College of Cardiology, 1999, 34, 810-814.	1.2	139
134	Assessment of Atrioventricular Junction Ablation and DDDR Mode-Switching Pacemaker Versus Pharmacological Treatment in Patients With Severely Symptomatic Paroxysmal Atrial Fibrillation. Circulation, 1997, 96, 2617-2624.	1.6	207
135	Prognostic significance of the extent of myocardial injury in acute myocardial infarction treated by streptokinase (the GISSI trial). American Journal of Cardiology, 1989, 63, 1291-1295.	0.7	114